Business Context and Reporting Period
Company: Ecolab Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 7, 2017
Reporting Period Covered: Fiscal years ended December 31, 2016 and 2015; Quarterly periods of 2016.
This filing provides supplemental unaudited financial information regarding reportable segment net sales and operating income. The data reflects a strategic realignment effective in the first quarter of 2017, specifically the establishment of a new Life Sciences operating segment to align with growth strategies in pharmaceutical and personal care manufacturing.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it references two exhibits containing the detailed data:
- Exhibit 99.1: Supplemental unaudited reportable segment net sales and operating income for the years ended December 31, 2016 and 2015.
- Exhibit 99.2: Supplemental unaudited reportable segment net sales and operating income for each quarter of 2016 and the twelve months ended December 31, 2016.
The data in these exhibits is presented using fixed currency exchange rates established by management at the beginning of 2017 to reflect international operations.
Material Changes Versus Prior Period
The filing highlights the following material changes in financial presentation compared to prior reports:
- Segment Restructuring: Establishment of the Life Sciences operating segment effective Q1 2017.
- Currency Methodology: Recalculation of international operations using fixed currency exchange rates set at the start of 2017.
- Operational Adjustments: Immaterial changes including the movement of certain customers and cost allocations between reportable segments.
These changes are intended to align financial reporting with the company's growth strategy and are not intended to replace the official presentations in the 2016 Form 10-Q or 2015/2016 Form 10-K filings.
Guidance, Outlook, and Risks
Management Commentary: The filing focuses on the strategic rationale for the new Life Sciences segment, citing alignment with pharmaceutical and personal care manufacturing operations.
Legal Disclaimer: The financial information provided in this 8-K and its exhibits is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, it is not subject to the liabilities of that Section and shall not be deemed incorporated by reference into any registration statement or other SEC document unless expressly set forth by specific reference.
Guidance: No specific forward-looking guidance or outlook figures are provided in the text of this filing.
Investor Verification Checklist
- Review Exhibit 99.1 and Exhibit 99.2 attached to the filing for the actual numerical data on segment net sales and operating income.
- Verify the impact of the new Life Sciences segment on historical comparability between 2015 and 2016.
- Confirm the specific fixed currency exchange rates used for the supplemental presentation to understand the variance from reported GAAP figures.
- Check the official Form 10-K and Form 10-Q filings for the primary, audited financial statements, as this 8-K is supplemental only.